BioCentury | Dec 15, 2014
Company News

Corticrine, Actinogen deal

...Actinogen acquired Corticrine, a spinout of Edinburgh BioQuarter, the commercialization arm of the College of Medicine...
...A$2 million though the placement of another 100 million shares valued at A$0.02 per share. Corticrine...
...it has completed a Phase I trial. The companies declined to provide other financial terms. Corticrine Ltd....
Items per page:
1 - 1 of 1
BioCentury | Dec 15, 2014
Company News

Corticrine, Actinogen deal

...Actinogen acquired Corticrine, a spinout of Edinburgh BioQuarter, the commercialization arm of the College of Medicine...
...A$2 million though the placement of another 100 million shares valued at A$0.02 per share. Corticrine...
...it has completed a Phase I trial. The companies declined to provide other financial terms. Corticrine Ltd....
Items per page:
1 - 1 of 1